Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target

Guggenheim analyst Vamil Divan has reiterated a Buy rating on Johnson & Johnson (NYSE: JNJ) and maintained a price target of $287 for the stock. This endorsement reflects confidence in the company's performance and potential growth.